Open for recruitment
Trial summary
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Trial details
Short title
ELEGANT / STML-ELA-0422
Diagnosis
Breast cancer
Type of treatment
Medical Oncology
Phase
III
Locations
Investigators
Principal Investigators
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.